CBD in cannabis could reduce psychosis risk from high strength skunk, study shows

Buffer effect could point to a protective mechanism that may help 'treat disorders like psychosis and addiction'

Alex Matthews-King
Health Correspondent
Wednesday 24 April 2019 06:07
Comments
CBD levels should be regulated alongside THC in countries where cannabis is legal, like Canada (pictured)
CBD levels should be regulated alongside THC in countries where cannabis is legal, like Canada (pictured)

Cannabidiol (CBD), a chemical derived from the cannabis plant, can counteract the effects of high strength "skunk" strains and may help to reduce the risk of serious mental health conditions like psychosis, according to a new study.

After using scans to study the effects of different strains of cannabis on the brain for the first time, the team from the University College London said boosting levels of CBD could act as a “buffer” to ill effects.

They found that strains with the same level of THC, the chemical which causes users to get “stoned”, but higher CBD caused less disruption to parts of the brain linked to addiction and psychosis.

Users also reported a reduction in feelings of being high and experts said this lent support to using high-CBD strains for medicinal uses.

“Over the last two decades, rates of addiction and psychosis linked to cannabis have been on the rise, while at the same time stronger strains of cannabis with more THC and less CBD have become increasingly common,” said Dr Matt Wall, lead author of the study which was published in the Journal of Psychopharmacology.

He added: “We have now found that CBD appears to buffer the user against some of the acute effects of THC on the brain.”

Cannabis contains hundreds of chemicals known as cannabinoids, with THC (tetrahydrocannabidiol) being the most abundant in modern strains followed by CBD.

In the UK, where recreational cannabis remains illegal and medicinal use in its infancy, the prevalence of skunk has been blamed for London having the highest rates of psychosis in Europe.

Meanwhile CBD oils are increasingly sold in health shops for an array of ailments despite limited evidence, thanks in part to decades of prohibition.

The UCL trial used MRI scans to study activation of different parts of the brain after using two strains, equivalent to a “skunk” strain with low CBD and a higher level.

It found that the low-CBD "skunk" strain disrupted signals from neurons in a region of the brain called the posterior cingulate and this led to users reporting feeling more stoned.

There was also interference in the network of neurons which underpin emotional and sensory information, known as the salience networks.

Support free-thinking journalism and attend Independent events

Disrupting these areas has been linked to addiction and psychosis, but CBD helped alleviate this and could point to a protective or medicinal use.

“If CBD can restore disruption to the salience network, this could be a neuroprotective mechanism to explain its potential to treat disorders of salience such as psychosis and addiction,” said Professor Val Curran.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in